Cardiomyopathy Due to Anthracyclines Latest Advances

Find the Latest Research About Cardiomyopathy Due to Anthracyclines

Last Updated: 06/30/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 1976 publications

CHK1 activates mitophagy to attenuate cardiac aging via inhibiting AHSA1-ubiquitination.

CHK1 activates mitophagy to attenuate cardiac aging via inhibiting AHSA1-ubiquitination.

Journal: Redox biology
Published: April 30, 2026

Multiomics Analysis Reveals the Protective Effect of a Novel Bioactive Peptide (BP1) in Cardiomyopathy Using a Zebrafish Model.

Multiomics Analysis Reveals the Protective Effect of a Novel Bioactive Peptide (BP1) in Cardiomyopathy Using a Zebrafish Model.

Journal: Journal of proteome research
Published: April 14, 2026

EV-Mediated Intracardiac Crosstalk Mitigates Doxorubicin-Induced Cardiotoxicity.

EV-Mediated Intracardiac Crosstalk Mitigates Doxorubicin-Induced Cardiotoxicity.

Journal: Circulation research
Published: April 08, 2026

Heart Disease in Survivors of Childhood Cancer: Data From the German Childhood Cancer Registry and Statutory Health Insurance Carriers (the VersKiK Study).

Heart Disease in Survivors of Childhood Cancer: Data From the German Childhood Cancer Registry and Statutory Health Insurance Carriers (the VersKiK Study).

Journal: Deutsches Arzteblatt international
Published: April 06, 2026

Bradyarrhythmias Associated with Oncologic Treatment-An Updated Review.

Bradyarrhythmias Associated with Oncologic Treatment-An Updated Review.

Journal: Cancers
Published: March 30, 2026

Cardioprotection in oncology: Mechanisms, risks and therapeutic strategies.

Cardioprotection in oncology: Mechanisms, risks and therapeutic strategies.

Journal: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
Published: March 30, 2026

Myopericarditis After Combined Idarubicin and Quizartinib in FLT3-ITD-Positive AML.

Myopericarditis After Combined Idarubicin and Quizartinib in FLT3-ITD-Positive AML.

Journal: JACC. Case reports
Published: March 11, 2026

Midkine, a heparin-binding growth factor, exacerbates heart failure in dilated cardiomyopathy via NRXN1 regulation and inflammatory responses.

Midkine, a heparin-binding growth factor, exacerbates heart failure in dilated cardiomyopathy via NRXN1 regulation and inflammatory responses.

Journal: The international journal of biochemistry & cell biology
Published: March 09, 2026

Targeted nano delivery of p53 DNA and carvedilol for the treatment of dilated cardiomyopathy in a rat model.

Targeted nano delivery of p53 DNA and carvedilol for the treatment of dilated cardiomyopathy in a rat model.

Journal: Nanomedicine (London, England)
Published: February 25, 2026

Molecular Insights into Doxorubicin-Induced Cardiotoxicity and Phytochemical-Based Cardioprotection: Challenges and Future Strategies.

Molecular Insights into Doxorubicin-Induced Cardiotoxicity and Phytochemical-Based Cardioprotection: Challenges and Future Strategies.

Journal: Drug metabolism reviews
Published: February 10, 2026

Discovery and Structure-Activity Relationship Studies of Diazepine Derivatives as a New Class of Ferroptosis Inhibitors with Potent Efficacy in the Doxorubicin-Induced Cardiomyopathy Model.

Discovery and Structure-Activity Relationship Studies of Diazepine Derivatives as a New Class of Ferroptosis Inhibitors with Potent Efficacy in the Doxorubicin-Induced Cardiomyopathy Model.

Journal: Journal of medicinal chemistry
Published: January 30, 2026

Gain-of-Function Variant TRPC6 A404V Is Associated With Doxorubicin-Related Cardiomyopathy.

Gain-of-Function Variant TRPC6 A404V Is Associated With Doxorubicin-Related Cardiomyopathy.

Journal: Circulation. Genomic and precision medicine
Published: January 28, 2026
Showing 1-12 of 1,976

Last Updated: 06/30/2026